Avadel Pharmaceuticals
AVDL
AVDL was delisted on the 11th of February, 2026.
45 hedge funds and large institutions have $55.9M invested in Avadel Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 13 increasing their positions, 10 reducing their positions, and 10 closing their positions.
98% more capital invested
Capital invested by funds: $28.2M → $55.9M (+$27.7M)
30% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 10
0.7% less ownership
Funds ownership: 52.49% → 51.79% (-0.7%)
8% less funds holding
Funds holding: 49 → 45 (-4)
40% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 10
75% less call options, than puts
Call options by funds: $23K | Put options by funds: $92K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
+$347K |
| 2 |
CIBC Private Wealth Group
Atlanta,
Georgia
|
+$258K |
| 3 |
Renaissance Technologies
New York
|
+$248K |
| 4 |
BCM
Brown Capital Management
Baltimore,
Maryland
|
+$214K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$123K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
-$1.08M |
| 2 |
BIP
Brandes Investment Partners
La Jolla,
California
|
-$461K |
| 3 |
Millennium Management
New York
|
-$93K |
| 4 |
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System
Harrisburg,
Pennsylvania
|
-$52.7K |
| 5 |
WS
Wedbush Securities
Los Angeles,
California
|
-$51K |
AVDL Hedge Fund Activity: Q2 2019 in Review
45 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in Avadel Pharmaceuticals (AVDL) for Q2 2019, worth a combined $55.9M — up 98% from $28.2M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of AVDL and 6 opened new positions — a net loss of 4 holders — while 10 trimmed existing stakes and 13 added.
The largest buyer was Ameriprise, adding an estimated $347K. The largest seller was Acadian Asset Management, cutting an estimated $1.08M.
- 45 institutional investors held Avadel Pharmaceuticals (AVDL) as of Q2 2019, down from 49 in Q1 2019.
- Funds reported $55.9M of Avadel Pharmaceuticals stock for Q2 2019, up 98% quarter-over-quarter.
- 6 funds opened new Avadel Pharmaceuticals positions in Q2 2019 and 10 closed out, a net change of -4 holders.
- The largest Avadel Pharmaceuticals buyer in Q2 2019 was Ameriprise, an estimated $347K added.
- The largest Avadel Pharmaceuticals seller in Q2 2019 was Acadian Asset Management, an estimated $1.08M sold.
Based on aggregated 13F filings for Q2 2019.